Ads
related to: vascepa effect on triglycerides and blood sugar- Co-Pay Program
Resources
to Support Your Patients
- Request Samples
Get patients started
with a 14-day sample
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Trial Results
See Clinical Data
and Trial
- Co-Pay Program
reviewscout.org has been visited by 100K+ users in the past month
wiserlifestyles.com has been visited by 100K+ users in the past month
amazon.com has been visited by 1M+ users in the past month
Search results
Results From The WOW.Com Content Network
On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels". [6] It is available as a generic medication. [8] In 2022, it was the 229th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [9] [10]
About REDUCE-IT ® REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline ...
Vascepa (icosapent ethyl) is a brand-name prescription medication. Doctors may prescribe it alongside dietary changes to reduce levels of triglyceride (a type of fat) in adults with severe ...
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association’s Scientific ...
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher.
Omega-3-acid ethyl esters are used in addition to changes in diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. [3] In the European Union and other major markets outside the US, omega-3-acid ethyl esters are indicated for hypertriglyceridemia by itself, or in combination with a statin for people with mixed dyslipidemia.